TCGA-CV-A45X-01A-21R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.045205479
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.190
- PROTEIN_SECRETION+0.180
- KRAS_SIGNALING_DN+0.120
- TGF_BETA_SIGNALING+0.100
- CHOLESTEROL_HOMEOSTASIS+0.080
- KRAS_SIGNALING_UP+0.070
- IL6_JAK_STAT3_SIGNALING+0.030
- P53_PATHWAY+0.030
- ESTROGEN_RESPONSE_EARLY+0.010
- PI3K_AKT_MTOR_SIGNALING+0.010
Top 10 suppressed
- E2F_TARGETS-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- HEDGEHOG_SIGNALING-0.340
- MYC_TARGETS_V1-0.340
- INTERFERON_ALPHA_RESPONSE-0.330
- ALLOGRAFT_REJECTION-0.320
- G2M_CHECKPOINT-0.300
- INTERFERON_GAMMA_RESPONSE-0.290
- ANDROGEN_RESPONSE-0.280
- OXIDATIVE_PHOSPHORYLATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A8HI-01A-11R-A38B-07 | — | — | 0.809 |
| 2 | MDT-AP-2993 | Med | Medulloblastoma | 0.762 |
| 3 | a3380ca6-6c65-4543-9bdf-957b26c1daaf | — | — | 0.760 |
| 4 | TCGA-GC-A3RD-01A-12R-A22U-07 | — | — | 0.752 |
| 5 | SRR6079994 | — | — | 0.749 |
| 6 | TCGA-P3-A6T4-01A-11R-A34R-07 | — | — | 0.745 |
| 7 | SRR12475149 | — | — | 0.743 |
| 8 | TCGA-CF-A47X-01A-31R-A23W-07 | — | — | 0.735 |
| 9 | TCGA-LT-A8JT-01A-11R-A36F-07 | — | — | 0.733 |
| 10 | dab9a230-f4f6-4692-863a-5fdcf516be24 | — | — | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |